WELCOME

Cyterix is developing novel cancer therapeutics based on a proprietary OncoCYP™ prodrug discovery approach that targets extra-hepatic cytochrome P450 enzymes that are over-expressed in the majority of cancers to a high frequency, but not in normal tissues. The company's mission is to discover and develop multiple classes of small molecule oncology prodrugs with a superior safety and efficacy profile to current cytotoxic drugs and molecularly targeted agents.